Neuphoria Therapeutics Inc. (NEUP)
NASDAQ: NEUP · Real-Time Price · USD
3.440
+0.025 (0.73%)
Jul 20, 2026, 1:00 PM EDT - Market open
Neuphoria Therapeutics Employees
As of June 30, 2025, Neuphoria Therapeutics had 8 total employees, including 7 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
8
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,178,892
Market Cap
18.59M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2025 | 8 | 0 | - | 7 | 1 |
| Jun 30, 2024 | 8 | - | - | 8 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Quince Therapeutics | 38 |
| Longeveron | 38 |
| Palatin Technologies | 29 |
| Tevogen Bio Holdings | 18 |
| Lipocine | 14 |
| Werewolf Therapeutics | 14 |
| Cellectar Biosciences | 11 |
NEUP News
- 23 days ago - Neuphoria Therapeutics confirms merger discussions with Scancell Holdings - TheFly
- 23 days ago - Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc - GlobeNewsWire
- 2 months ago - Neuphoria Therapeutics downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 2 months ago - Neuphoria Therapeutics Quarterly report: Q3 2026 - Filings
- 5 months ago - Neuphoria Therapeutics Quarterly report: Q2 2026 - Filings
- 8 months ago - Neuphoria announces ISS recommends shareholders vote ‘FOR’ director nominees - TheFly
- 8 months ago - Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director Nominees - GlobeNewsWire
- 8 months ago - Neuphoria Therapeutics Proxy statement: Proxy filing - Filings